Refine by
Heart Data Articles & Analysis
35 news found
A third site is an academic medical center and is recognized as one of the top heart failure centers in the U.S. with more than 800 physicians in 200 specialties serving patients in Virginia. ...
Oak Ridge, TN – March 23, 2023 — Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new pilot randomized control trial (RCT) data from Duke Heart validating the greater accuracy of the Company’s BVA-100 diagnostic in optimizing decongestion therapy for heart failure ...
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 diagnostic in optimizing individualized therapy for heart failure patients. Data were presented at the Technology Heart Failure Therapeutics Conference, which ...
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new pilot randomized control trial (RCT) data from Duke Heart validating the greater accuracy of the Company’s BVA-100 diagnostic in optimizing decongestion therapy for heart failure patients and pointed to a strong signal toward ...
Oak Ridge, TN – March 23, 2023 — Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 diagnostic in optimizing individualized therapy for heart failure patients. Data were presented at the Technology ...
The Journal of Cardiac Failure is the official peer reviewed journal of the Heart Failure Society of America and the Japanese Heart Failure Society. Data from this study was cited at the 2022 Annual Heart Failure Society of America meeting in a session focused on congestion measurement which called for the use of the BVA-100 ...
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data from the Mayo Clinic in Rochester, NY validating the benefits of the Company’s BVA-100 blood test for patients with heart failure. Data were presented at the Heart Failure Society of America (HFSA) Annual ...
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 blood test for heart failure patients. Data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2022 – which ...
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 diagnostic blood test in reducing hospital length of stay (LOS) for heart failure (HF) patients. Data were presented at the Heart Failure Society of America ...
CardioWise: CardioWise is an AI cardiac image analysis company that simplifies the diagnosis of heart disease enabling a quantitative diagnostic evaluation of the heart system using CT data. CardioWise analysis will provide caregivers with next generation algorithms and data to help physicians to make better more informed ...
Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced positive data from the SIRONA 2 clinical trial evaluating safety and efficacy of its Cordella™ Pulmonary Artery Pressure Sensor System (Cordella Sensor) in New York Heart Association (NYHA) class III ...
Non-invasive arrhythmia technology maps using only the data from a 12 lead ECG vMap provides actionable mapping results in minutes. ...
It will explore the potential for PiCSO therapy to improve the outcomes of patients with heart attacks affecting the inferior side of the heart. The study builds upon the data from the First-InMan study that we published in 20213 . We know that improving outcomes for patients with large heart attacks remains an important unmet ...
The conventional one-lead patch Holter monitor has been the standard of care for cardiac monitoring, typically worn from 24 hours up to a couple weeks and requires patients to send back the device for data uploading, after which a formal analysis can be performed. This can take up to 2 weeks after the study has ended. Biotres has the ability to disrupt the market with its ...
Biotres is designed to continuously record ECG data for early detection of cardiac arrhythmias The Biotres addresses the $2 Billion-dollar holter market Biotricity Inc. ...
Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF)'s Wayne Paterson tells Proactive about the 30-day follow-up data just in from the company’s flagship heart valve, currently being tested in humans for the first time. The valve solves the problem of younger and more active heart patients who need a valve that performs better and lasts ...
Food and Drug Administration (FDA) 510(k) clearance for its novel computational ECG mapping system, vMap™. vMap is designed to map potential arrhythmia sources (hot spots) associated with stable or unstable arrhythmias anywhere in the heart – including all four chambers, the septal wall, and the outflow tracts – in less than three minutes using only ECG ...
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, today announces that it has received final approval from the Patient Protection Committee (CPP ...
ByCarmat
VUNO Med®–DeepCARS™ is a breakthrough AI-driven medical device that analyzes the potential risk of cardiac arrest using four primary vital signs: Blood Pressure (diastolic and systolic) Respiratory Rate Heart Rate Body Temperature These data points are collected from the electronic medical record (EMR) of hospitalized patients. ...
Double-blind, randomized trial data show a clinically meaningful and statistically significant net reduction of 8.1 mmHg in 24-hour ambulatory systolic blood pressure at 6 months in treated vs. control patients Very high (85%) response rate to therapy despite 81% of treated patients having isolated systolic hypertension (ISH), a more dangerous and difficult to treat form of ...